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Objective: Currently available synthetic polymer vascular patches used in cardiovascular surgery have shown serious
shortcomings, including thrombosis, calcification, infection, and lack of growth potential. These problems may be
avoided by vascular patches tissue-engineered with autologous stem cells and biodegradable polymeric materials. The
objective of this study was to develop a tissue-engineered vascular patch by using autologous bone marrow–derived cells
(BMCs) and a hybrid biodegradable polymer scaffold.
Methods: Hybrid biodegradable polymer scaffolds were fabricated from poly(lactide-co--caprolactone) (PLCL) copoly-
mer reinforced with poly(glycolic acid) (PGA) fibers. Canine bone marrow mononuclear cells were induced in vitro to
differentiate into vascular smooth muscle cells and endothelial cells. Tissue-engineered vascular patches (15 mm wide 
30 mm long) were fabricated by seeding vascular cells onto PGA/PLCL scaffolds and implanted into the inferior vena
cava of bone marrow donor dogs.
Results: Compared with PLCL scaffolds, PGA/PLCL scaffolds exhibited tensile mechanical properties more similar to
those of dog inferior vena cava. Eight weeks after implantation of vascular patches tissue-engineered with BMCs and
PGA/PLCL scaffolds, the vascular patches remained patent with no sign of thrombosis, stenosis, or dilatation.
Histological, immunohistochemical, and scanning electronmicroscopic analyses of the retrieved vascular patches revealed
regeneration of endothelium and smooth muscle, as well as the presence of collagen. Calcium deposition on tissue-
engineered vascular patches was not significantly different from that on native blood vessels. Immunofluorescent double
staining confirmed that implanted BMCs survived after implantation and contributed to regeneration of endothelium
and vascular smooth muscle in the implanted vascular patches.
Conclusions: This study demonstrates that vascular patches can be tissue-engineered with autologous BMCs and hybrid
biodegradable polymer scaffolds. ( J Vasc Surg 2006;44:1329-40.)
Clinical Relevance: The purpose of this study was to test the feasibility of engineering a vascular patch with autologous
bone marrow–derived cells and a hybrid biodegradable scaffold in a canine model. Eight weeks after implantation, the
tissue-engineered vascular patches showed regeneration of vascular tissues with no sign of thrombosis, stenosis, or
dilatation. This preliminary study demonstrates that a tissue-engineering strategy using autologous stem cells and a
biocompatible, biodegradable polymer scaffold can be applied to repair vascular wall defects.Tissue-engineered vascular patches could be used to
replace patches made of nondegradable synthetic polymers
or xenogenic tissues. In the tissue-engineering approach,
autologous vascular cells seeded onto biodegradable poly-
mer scaffolds regenerate vascular tissues, with endothelium,
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doi:10.1016/j.jvs.2006.07.032in vivo. The polymer scaffold degrades completely in vivo,
resulting in autologous vascular tissue formation free of
foreign material. Tissue-engineered vascular patches are
thus antithrombogenic, biocompatible, durable, and capa-
ble of growth and repair. Recently, vascular patches tissue-
engineered with autologous vascular cells and biodegrad-
able polymer scaffolds made of poly(lactic-co-glycolic acid)1
or poly-4-hydroxybutyrate2 have shown vascular tissue re-
generation in vivo.
The ideal tissue-engineered vascular patch would be
constructed of a biodegradable and biocompatible material
sufficiently strong and elastic to resist the high and dynamic
pressure of blood flow in vivo. Recent in vitro studies have
demonstrated that elastic poly(lactide-co-ε-caprolactone)
(PLCL) scaffolds3 can be used to engineer vascular smooth
muscle (SM)4 and blood vessels5 under conditions of cyclic
mechanical strain. Furthermore, it is well known that PLCL
copolymer has the appropriate biodegradability and bio-
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may not be appropriate for tissue engineering of a vascular
patch in vivo, however, because their mechanical properties
are significantly different from those of native blood vessels.
Bone marrow–derived cells (BMCs) are an alternative
cell source for tissue engineering of vascular patches be-
cause isolation of autologous vascular cells from vessel
biopsy requires additional invasive surgical procedures. Re-
cently it has been reported that BMCs are capable of
differentiating into endothelial cells (ECs)6-8 and vascular
SM cells (SMCs).9-11 The use of BMCs as a cell source for
vascular patch engineering is considered less invasive than
harvesting vascular cells from autologous blood vessels.
Presumably, BMCs could also be used as a cell source for
patients lacking blood vessels suitable for harvest as a result
of pre-existing vascular disease or vessel use in previous
procedures.
In this study, we developed a tissue-engineered vascular
patch by using autologous BMCs and a hybrid biodegrad-
able polymer scaffold. To improve the tensile mechanical
properties of the PLCL scaffold, the elastic PLCL scaffold
was reinforced with poly(glycolic acid) (PGA) fibers. PGA/
PLCL vascular patches were seeded with ECs and SMCs
differentiated from BMCs and implanted in the inferior
vena cava (IVC) of bone marrow donor dogs. Eight weeks
after implantation, vascular tissue regeneration in the tissue-
engineered vascular patches was investigated by histologi-
cal, immunohistochemical, and scanning electron micro-
scopic analyses.
MATERIALS AND METHODS
Preparation of PGA/PLCL scaffolds. PLCL 50:50
copolymer (molecular weight, 185,000) was synthesized
from L-lactide (100 mmol) and ε-caprolactone (100 mmol)
in the presence of stannous octoate (1 mmol) and 1,6-
hexanediol (0.5 mmol) at 150°C for 24 hours. The product
was dissolved in chloroform and filtered through a
0.45-m pore membrane filter. Precipitation of the poly-
mer was accomplished by pouring the polymer solution
into an excess of methanol. It was then filtered and dried
under a vacuum. PGA/PLCL hybrid scaffolds were fabri-
cated by the solvent-casting and particle-leaching method.
Sodium chloride particles (50-100 m) were added to a
20% (wt/vol) PLCL solution in chloroform and mixed to
homogeneity. The polymer-salt solution was poured and
cast onto glass plates containing PGA fibers (12 m in
diameter; Albani International, Mansfield, Mass) with a
bulk density of 26 mg/cm3. The solvent was evaporated for
48 hours at room temperature and then removed com-
pletely under a vacuum for 24 hours. The resulting PGA/
PLCL-salt composite scaffolds were immersed in distilled
water with shaking for 3 days to leach out salt. Salt-free
PGA/PLCL scaffolds were freeze-dried for 24 hours and
sterilized with ethylene oxide gas.
Measurement of tensile properties. Tensile proper-
ties of the scaffolds were measured as previously de-
scribed.12 In brief, after 0, 1, 2, 4, and 8 weeks of incuba-
tion in phosphate-buffered saline (PBS; Sigma, St Louis,Mo) with shaking at 37°C, tensile properties of PGA/
PLCL and PLCL scaffolds were measured by using an
Instron mechanical tester (model 5567; Instron, Canton,
Mass). Tests were performed by using a 10-N maximum
load cell with a cross-head speed of 1 mm/min. Tensile
strength and elongation of PGA/PLCL scaffolds (n  3)
were calculated from the stress-strain curve and compared
with those of PLCL scaffolds (n  3).
Mercury porosimetry. The pore size distribution and
porosity of the PGA/PLCL scaffolds were measured by
using a mercury intrusion porosimeter (AutoPore IV 9500;
Micromeritics Instrument Co, Norcross, Ga) in mercury
intrusion under an increasing pressure from 4.8 to 345 kPa.
The determination of porosity and pore size was based on
the relationship between the applied pressure and the pore
diameter into which mercury intrudes, according to the
Washburn equation:
D (4cos) ⁄P ,
where P is the applied pressure, D is the pore diameter,  is
the surface tension of the mercury (480 mN/m), and  is
the contact angle between mercury and the pore wall, taken
as 140°.
BMC isolation and culture. BMC isolation, culture,
and differentiation were performed as previously de-
scribed.13-15 In brief, bone marrow (30 mL per dog) was
aspirated from the humeri of healthy mongrel dogs (12
months old; 20-25 kg; n  4) with a syringe containing
heparin (100 U/mL of bone marrow). Aspirated bone
marrow was mixed with an equal volume of PBS solution
and centrifuged on a Ficoll-Paque density gradient (Amer-
sham Biosciences, Arlington Heights, Ill) for 30 minutes at
2000 rpm. Bone marrow mononuclear cells (BMMNCs)
were isolated from the layer between the Ficoll-Paque
reagent and blood plasma and washed three times in PBS.
BMMNCs were cultured under conditions for EC and
SMC differentiation and proliferation for 3 weeks before
cell seeding. For differentiation into SMCs, BMMNCs
were cultured in Medium 199 (Gibco BRL, Gaithersburg,
Md) supplemented with 10% (vol/vol) fetal bovine serum
(Gibco BRL), 100 U/mL penicillin (Gibco BRL), and 0.1
mg/mL streptomycin (Gibco BRL) in humidified air with
5% carbon dioxide at 37°C. For differentiation into ECs,
BMMNCs were grown on culture dishes coated with
1 g/cm2 human fibronectin (Sigma) in endothelial
growth medium-2 medium (Cambrex, Walkersville, Md)
supplemented with human vascular endothelial growth fac-
tor (10 ng/mL; PeproTech, Rocky Hill, NJ), human basic
fibroblast growth factor (2 ng/mL; PeproTech), human
epidermal growth factor (10 ng/mL; PeproTech), human
insulin-like growth factor 1 (5 ng/mL; PeproTech), and
ascorbic acid.
BMC characterization. ECs and SMCs differentiated
from BMMNCs were characterized by immunochemical
staining. EC staining was performed by using antibodies
raised against von Willebrand factor (vWF; DAKO, Car-
penteria, Calif) and CD31 (DAKO). SMCs were stained
with antibodies raised against SM -actin (DAKO) and SM
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to confirm endothelial and SM differentiation of canine
BMCs in the previous studies.13-16 The staining signal was
visualized with an avidin-biotin complex immunoperoxi-
dase kit (Vectastain Elite ABC kit; Vector Laboratories,
Burlingame, Calif) and 3,3=-diaminobenzidine substrate
solution kit (Vector Laboratories). Negative immuno-
chemical staining without the use of the primary antibodies
raised against vWF and SM -actin was performed.
Cell seeding and in vitro maintenance of cell-seeded
scaffolds. BMC labeling and seeding were performed as
previously described.13-15 After cell seeding, BMC-seeded
vascular patches were cultured in vitro for 1 week under a
static condition. In brief, SMCs and ECs, both differenti-
ated from BMMNCs, were labeled with 1 g/mL of a
fluorescent cell tracker, chloromethyl-1,1=-dioactadecyl-
3,3,3=,3=-tetramethylindocarbocyanine perchlorate (CM-
DiI; C-7001; Molecular Probes, Eugene, Ore), before
seeding. CM-DiI is a membrane-incorporated dye. SMCs
(4.0 107/mL) were uniformly seeded onto PGA/PLCL
patch scaffolds (15 mm wide; 30 mm long), followed 2
hours later by seeding of ECs (1.0  107/mL) onto the
luminal sides of the scaffolds. Before implantation, BMC-
seeded patch scaffolds were cultured in Medium 199 sup-
plemented with 20% (vol/vol) fetal bovine serum, human
vascular endothelial growth factor (10 ng/mL), and hu-
man basic fibroblast growth factor (2 ng/mL) for 1 week in
humidified air with 5% carbon dioxide at 37°C. The cell-
seeded patches were not preconditioned with shear stress of
venous levels before implantation.
Implantation. PGA/PLCL vascular patches seeded
with BMCs were implanted into the IVCs of bone marrow
donor dogs (n  4). Adult mongrel dogs (20-25 kg) were
anesthetized with intramuscular injection of ketamine (30
mg/kg) and intravenous injection of pentobarbital (30
mg/kg). Ventilation with a mixture of oxygen, nitrogen,
and isoflurane was maintained during the operation.
Through a midline abdominal incision, the IVC was ex-
posed, and surrounding tissues were dissected from the
IVC. After heparin (100 U/kg) was administered intrave-
nously, the proximal and distal portions of the IVC were
clamped. The IVC was opened in the longitudinal direction
and washed with a heparin solution. The opened IVC was
closed with the tissue-engineered vascular patch by using
6-0 polypropylene sutures (Ethicon, Somerville, NJ). No
anticoagulants or antiplatelets were administered after sur-
gery. There was no mortality in the procedure for patch
implantation. All animals received humane care in compli-
ance with the Guide for the Care and Use of Laboratory
Animals published by Samsung Medical Center.
Histological and immunohistochemical analyses.
Midportion segments of the vascular patches retrieved 8
weeks after implantation were fixed in 10% (vol/vol) buff-
ered formaldehyde solution, dehydrated with a graded
ethanol series, and embedded in paraffin. Specimens were
sliced into 4-m sections and stained with hematoxylin and
eosin (H&E). Collagen in the retrieved vascular patches
was stained by using the Masson trichrome method. Spec-imens were also stained immunohistochemically for vWF
and SM -actin. Immunohistochemical staining of the
specimens for osteopontin (Santa Cruz Biotechnology,
Santa Cruz, Calif) was performed to examine calcification
in the patches. For double staining of CM-DiI–labeled cells
and vWF-positive or SM -actin–positive cells, tissue sec-
tions were stained immunofluorescently for vWF and SM
-actin by using fluorescein isothiocyanate–conjugated
anti-mouse immunoglobulin G secondary antibodies (Jack-
son ImmunoResearch Laboratories, West Grove, Pa).
Double-stained sections were analyzed with a confocal
microscope (LSM510; Carl Zeiss, Oberkochen, Germany).
Scanning electron microscopy. Polymer scaffolds,
cell-seeded scaffolds, and tissue-engineered vascular patches
at 8 weeks after implantation were analyzed by scanning
electron microscopy. Polymer scaffolds were coated with
gold by using a sputter coater (Cressington 108; Cressing-
ton Scientific Instruments, Cranberry, Pa) and examined
with a scanning electron microscope (JSM-6330F; JEOL,
Tokyo, Japan). Cell-seeded scaffolds and tissue-engineered
vascular patches at 8 weeks after implantation were fixed in
1% (vol/vol) buffered glutaraldehyde and 0.1% (vol/vol)
buffered formaldehyde for 30 minutes and 24 hours, re-
spectively, dehydrated with a graded ethanol series, and
dried. Dried samples were mounted on aluminum stubs,
sputter-coated with gold, and examined with the scanning
electron microscope.
Measurement of calcium content. The calcium con-
tents of tissue-engineered vascular patches (n  4) and
native IVCs (n  4) were measured by using a previously
reported method.17 After the retrieved tissues were rinsed
twice with PBS and homogenized with 0.6 N HCl, calcium
was extracted by shaking for 4 hours at 4°C. The lysate was
then centrifuged at 1000g for 5 minutes, and the superna-
tant was used to determine calcium content. The calcium
content in the tissues was quantified spectrophotometri-
cally with cresolphthalein complexone (Sigma). Three min-
utes after the addition of reagents, the absorbance of the
samples was read at 575 nm by using a microplate reader
(Multiskan Spectrum; Thermo Electron Co, Vantaa, Fin-
land). The calcium concentration was calculated from a
standard curve generated from a serial dilution of a calcium
standard solution (Sigma).
Statistical analysis. Quantitative data are expressed as
mean  SD. Statistical analysis was performed with the
unpaired Student t test by using InStat software (InStat
3.0; GraphPad Software Inc, San Diego, Calif). P  .05
defined statistical significance.
RESULTS
Hybrid biodegradable polymer scaffolds (Fig 1, A) for
vascular patches were prepared from PLCL copolymer and
PGA fibers. Scanning electron microscopic examination of
the scaffolds showed porous structures in the cross section
(Fig 1, B) and luminal surface (Fig 1, C) of the scaffolds,
which would provide appropriate microenvironments for
cell adhesion and growth. A scanning electron micrograph
of the scaffolds indicated PGA fibers embedded in the
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porosimetric analysis revealed that the porosity and average
pore size of the scaffolds were approximately 75% and 80
m, respectively. After 0, 1, 2, 4, and 8 weeks of incubation
under physiological conditions, tensile properties of PGA/
PLCL scaffolds were measured and compared with those of
PLCL scaffolds fabricated by the same method. Tensile
tests showed PGA/PLCL scaffolds to have higher tensile
strength (Fig 2, A) but lower tensile elongation (Fig 2, B)
than PLCL scaffolds at all time points. Notably, PGA/
PLCL hybrid scaffolds were more similar to native IVCs
than to PLCL scaffolds in terms of tensile properties.
BMMNCs were induced to differentiate into ECs and
SMCs in vitro. The ECs showed a typical cobblestone mor-
phology (Fig 3, A) and expressed vWF (Fig 3, B) and CD31
(Fig 3, C), both EC phenotypic markers. In control staining
without the use of primary antibody, the ECs stained nega-
tively for vWF (Fig 3, D). SMCs showed morphology similar
to that of differentiated SMCs (Fig 3, E) and expressed SM
-actin (Fig 3, F) and SM myosin heavy chain (Fig 3, G), both
of which mark the SMC contractile phenotype. In control
staining without the use of primary antibody, the SMCs
stained negatively for SM -actin (Fig 3, H). Cell immuno-
chemistry showed that almost all ECs and SMCs differenti-
ated from BMMNCs expressed the phenotypic markers for
EC and SMC, respectively. Fibroblast contamination was not
observed during the differentiation process. BMCs were pas-
Fig 1. Vascular patch scaffold fabricated from poly(lac
poly(glycolic acid) (PGA) fibers. (A) Gross view of a PG
scale is in centimeters. Scanning electron micrographs of
surface (original magnification, 200), and (D) externa
scaffold are shown. Scale bars  200 m.saged twice in vitro to obtain the cell number for cell seeding.After culture for 3 weeks, ECs and SMCs were used for
seeding without purification.
PGA/PLCL vascular patch scaffolds were seeded with
ECs and SMCs and maintained in vitro for 1 week to allow
for cell adherence. Seeded cells adhered well onto PGA/
PLCL vascular patch scaffolds. H&E staining of the cross
section of cell-seeded patch scaffolds showed that a large
number of seeded cells were present in the scaffolds (Fig 4,
A). Scanning electron micrographic examination of the
luminal surface of seeded scaffolds showed cell adhesion
and complete coverage onto scaffold surfaces (Fig 4, B).
Immunohistochemical staining of seeded scaffolds for vWF
(Fig 4, C) and SM -actin (Fig 4, D) identified ECs and
SMCs in the scaffolds, respectively. CM-DiI–labeled cells
in the patch scaffolds were confirmed by confocal micros-
copy (Fig 4, E).
Tissue-engineered vascular patches (Fig 5, A) replaced
segments of canine IVCs without scaffold rupture or
deformation (Fig 5, B). At 8 weeks after implantation, all
patch-implanted IVCs were patent. No signs of thrombus
formation, stenosis, or dilatation were observed in the
explanted patches (Fig 5, C). H&E staining of the patches
retrieved after 8 weeks of implantation showed vascular
tissue formation (Fig 6, A). Masson trichrome staining
also indicated significant amounts of collagen in the vascu-
lar patches (Fig 6, B). Immunohistochemical analysis re-
co-ε-caprolactone) (PLCL) copolymer reinforced with
LCL patch scaffold (15 mm wide  30 mm long). The
ross section (original magnification,100), (C) luminal
ace (original magnification, 70) of PGA/PLCL patchtide-
A/P
(B) c
l surfvealed vWF-positive cells on the luminal sides of the
was not significantly different (P 	 .05) from that of native blood vessels.
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marrow mononuclear cells (BMMNCs) showed a cobblestone morphology (original magnification,100) and stained
positively for (B) von Willebrand factor (vWF; original magnification, 400) and (C) CD31 (original magnification,
400). In control staining without the use of primary antibody, ECs derived from BMMNCs stained negatively for
(D) vWF (original magnification, 400). (E) Smooth muscle cells (SMCs) derived from BMMNCs showed the
morphology of mature SMCs (original magnification, 200) and stained positively for (F) smooth muscle (SM)
-actin (original magnification, 200) and (G) SM myosin heavy chain (original magnification, 200). In control
staining without the use of primary antibody, SMCs derived from BMMNCs stained negatively for (H) SM -actinFig 2. Tensile mechanical properties of native blood vessels (canine inferior venae cavae [IVCs]; n  3) and
poly(glycolic acid) (PGA)/poly(lactide-co-ε-caprolactone) (PLCL) (n  3) and PLCL scaffolds (n  3) after
incubation in phosphate-buffered saline with shaking at 37°C for various time periods. A, Tensile strength of
PGA/PLCL scaffolds was significantly higher (P  .05) than that of PLCL scaffolds at 0, 1, 2, and 8 weeks after
incubation.B,Tensile elongation of PGA/PLCL scaffolds was significantly lower (P .05) than that of PLCL scaffolds
at 0, 1, 2, and 4 weeks after incubation. At 4 and 8 weeks after incubation, tensile elongation of PGA/PLCL scaffolds(original magnification, 200). Scale bars  30 m.
bar 
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stained positively for SM -actin (Fig 6, D). The volume of
cells in the patches increased after implantation because of
cell migration from surrounding tissues. Scanning electron
microscopic examination confirmed the presence of endo-
thelium similar to native endothelium (Fig 7). The calcium
content (2.52  1.97 g/mg of dry tissue; n  4) of the
tissue-engineered vascular patches at 8 weeks of implanta-
tion did not differ significantly (P 	 .05) from that of
native IVCs (1.48 0.64g/mg of dry tissue; n 4), thus
indicating that calcification in tissue-engineered patches
was not severe (Fig 8, A). Immunohistochemical staining
Fig 4. Preimplantation examinations of bone marrow–d
and eosin–stained section (original magnification, 400
week after cell seeding [black arrow, poly(glycolic acid) fi
arrows, cellular portion]. Scale bar  100 m. (B) Scan
patch 1 week after BMC seeding (original magnification
is shown of cell-seeded vascular patches for (C) von Will
m) and (D) smooth muscle -actin (original magnific
dioactadecyl-3,3,3=,3=-tetramethylindocarbocyanine per
seeding (original magnification, 200) are shown. Scalefor osteopontin showed that the vascular patches retrieved8 weeks after implantation stained negatively for osteopon-
tin (Fig 8, B), as did native IVCs (Fig 8, C). This may
support the result of calcium content quantification.
Implanted cells survived and participated in vascular
tissue formation in vivo. Immunofluorescent staining for
vWF and SM -actin confirmed the regeneration of endo-
thelium (Fig 9, A) and SM (Fig 9, D) in vascular patches
retrieved 8 weeks after implantation. Cells labeled with a
fluorescent carbocyanine dye (CM-DiI) before seeding and
implantation were identified in the luminal (Fig 9, B) and
medial (Fig 9, E) portions of retrieved vascular patches.
Immunofluorescent double staining showed that vWF-
d cell (BMC)-seeded vascular patches. (A) Hematoxylin
ssue-engineered vascular patch maintained in vitro for 1
black arrowheads, poly(lactide-co-ε-caprolactone); white
electron micrograph of the luminal surface of a vascular
0). Scale bar  30 m. Immunohistochemical staining
d factor (original magnification, 400; scale bar  100
, 400; scale bar  100 m). (E) Chloromethyl-1,1=-
ate–labeled cells in the patch scaffolds 1 week after cell
200 m.erive
) of ti
ber;
ning
, 60
ebran
ation
chlorpositive and CM-DiI–positive cells (yellow, arrows; Fig 9, C)
d into
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Double staining also showed the presence of SM -actin–
and CM-DiI–positive cells (yellow, arrows; Fig 9, F) in the
medial parts of explanted patches. These results suggest
that cells survived after implantation and contributed, in
part, to regeneration of endothelium or SM. BMC differ-
entiation into nonvascular lineage cells was not observed in
the retrieved patches. All CM-DiI–labeled (implanted) cells
(red; Fig 9, B and E) expressed vascular tissue–specific markers
such as vWF (Fig 9, C; yellow) or SM -actin (Fig 9, F;
yellow).
DISCUSSION
Currently available synthetic vascular grafts used in car-
diovascular surgery present serious problems, including
thrombosis, calcification, infection, and lack of growth poten-
tial. A tissue-engineering approach using autologous vascular
cells and a biodegradable polymer scaffold has been proposed
and tested to overcome these limitations.1,2,18,19 Recently,
BMCs capable of differentiating into multiple lineages of cells
were shown to be obtainable by less invasive processes than
before and have thus been explored as an alternative cell
source for tissue engineering of the cardiovascular system. In
this study, we developed a tissue-engineered vascular patch by
Fig 5. Implantation and explantation of tissue-enginee
poly(lactide-co-ε-caprolactone) vascular patch seeded w
The scale is in centimeters. B, Surgical implantation of ti
the inferior vena cava (IVC) segments of bone marrow do
after implantation. A vascular patch engineered with B
thrombosis. Arrows indicate the vascular patch implanteusing autologous BMCs and a hybrid biodegradable polymerscaffold of elastic PLCL scaffolds reinforced with PGA fibers.
The PGA/PLCL scaffolds exhibited tensile mechanical prop-
erties more similar to those of native blood vessels than did
scaffolds of PLCL alone. Tissue-engineered vascular patches
remained patent 8 weeks after implantation and showed
regeneration of vascular tissues with no signs of thrombosis
or dilatation.
Our previous study reported that vascular patches made of
autologous BMCs and decellularized tissue matrices showed
vascular tissue regeneration in canine models.13 Decellular-
ized tissue matrix fabricated from native blood vessel has also
shown usefulness as a biomaterial for artificial allogenic vascu-
lar grafts,13-15,20,21 yet allogenic decellularized tissue matrices
have a limited availability for human clinical application be-
cause of donor shortages. Synthetic biodegradable polymer
scaffolds with mechanical and physical characteristics appro-
priate for vascular grafts may solve these problems.
Selection of a reliable scaffold is critical for engineering
vascular tissues under mechanically dynamic in vivo environ-
ments such as in blood vessels. Appropriate scaffolds for these
applications should have elastic mechanical properties and a
proper tensile strength. In addition, the scaffolds should allow
for appropriate interactions with seeded cells, so as to induce
vascular tissue formation. PLCL copolymer-derived scaffolds
ascular patches. A, Gross view of a poly(glycolic acid)/
ne marrow–derived cells (BMCs) before implantation.
ngineered vascular patches. The vascular patch replaced
ogs. C, Gross view of a vascular patch retrieved 8 weeks
showed a smooth luminal surface without any sign of
the IVC. The scale is in centimeters.red v
ith bo
ssue-e
nor d
MCshave recently shown applicability as materials for tissue engi-
week
VC;
ineere
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that PLCL scaffolds possess elastic mechanical properties and
promote appropriate cellular interactions.3,4 It has further
been reported that SMCs adhere well and exhibit proliferation
on PLCL scaffolds in vitro.4 Another study reported that
SMCs seeded onto tubular PLCL scaffolds formed functional
SM tissues in vitro when exposed to pulsatile medium flow in
a bioreactor.5 Although PLCL scaffolds have shown appro-
priate properties through in vitro studies, the tensile mechan-
ical properties of PLCL scaffolds are significantly different
Fig 6. Histologic and immunohistochemical analyses
A, Hematoxylin and eosin staining of retrieved patches sh
100; scale bar  200 m). B, Masson trichrome stain
100; scale bar  200 m). C, Cells on the luminal sid
factor, thus indicating endothelium regeneration (origin
histochemical staining for smooth muscle (SM) -actin
regeneration of SM tissue.
Fig 7. Scanning electron microscopic examinations for
ated in the tissue-engineered vascular patches retrieved 8
The endothelium of native canine inferior vena cava (I
representative images of the luminal surface of tissue-engfrom those of native blood vessels and are not appropriate foruse in vascular patches in vivo. The tensile properties of PLCL
scaffolds could be improved by reinforcement with proper
biodegradable polymers, so as to be more similar to those of
native blood vessels.
A PLCL scaffold with improved mechanical properties
may be useful as a biomaterial for reconstruction of cardiovas-
cular tissues in vivo. Several animal studies have shown that
SMC-seeded PLCL scaffolds reinforced with a knitted poly-
L-lactide fabric repaired the right ventricular outflow tract and
improved left ventricular aneurysm repair.22,23 Recently,
ascular patches retrieved 8 weeks after implantation.
regeneration of vascular tissues (original magnification,
ndicated collagen regeneration (original magnification,
retrieved patches stained positively for von Willebrand
gnification, 400; scale bar  100 m). D, Immuno-
inal magnification, 400; scale bar  100 m) showed
rmation of endothelium. A, The endothelium regener-
s after implantation (original magnification,1500). B,
original magnification, 1500). These images are the
d vascular patches and native IVCs. Scale bars 20 m.of v
owed
ing i
es of
al ma
(origconfilarge-diameter vascular graft scaffolds were developed by us-
rs 
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fabric,24-26 and in this study, hybrid polymer scaffolds for
vascular wall reconstruction were fabricated from PLCL co-
polymer reinforced with PGA fibers. These PGA/PLCL scaf-
folds exhibited higher tensile strength than did PLCL scaf-
folds. However, the tensile strength of these PGA/PLCL
scaffolds was reduced at 8 weeks compared with that of native
IVCs (Fig 2, A). Because the test for measurement of tensile
properties was performed under in vitro conditions without
vascular tissue regeneration, only degradation of scaffolds
occurred, and mechanical compensation for the reduced ten-
sile strength by vascular tissue formation was not taken into
account. If these scaffolds were implanted in vivo, vascular
tissues regenerated in the scaffolds could compensate for the
reduced tensile strength of the scaffolds. Although the tensile
elongation of PGA/PLCL scaffolds was lower than that of
PLCL scaffolds, PGA/PLCL scaffolds exhibited tensile elon-
gation similar to that of native blood vessels (Fig 2, B). These
mechanical characteristics of PGA/PLCL scaffolds may indi-
cate that the scaffolds would not deform over time in vivo.
PGA/PLCL scaffolds also maintained the scaffold structure
and dimensions until seeded cells could form tissues with their
own extracellular matrices. Moreover, PGA/PLCL vascular
patches seeded with BMCs were remodeled into vascular
Fig 8. Examination of calcification in vascular patches r
tissue-engineered vascular patches at 8 weeks after impla
calcium content of tissue-engineered vascular patches (n
that of native IVCs (n  4). Immunohistochemical s
magnification, 100), (C) native IVCs (original magni
magnification, 400) for osteopontin is shown. Scale batissues without stenosis or dilatation in the IVCs of caninemodels. Further improvement in mechanical properties of the
PGA/PLCL scaffolds might be possible through control of
PGA fiber content, porosity, and pore size. In this study, the
tensile properties of the PGA/PLCL scaffolds after cell seed-
ing were not measured. It is known that PGA and PLCL
biodegradation mainly results from simple hydrolysis and not
from enzymatic degradation. Thus, cells seeded on the scaf-
folds may not significantly affect the mechanical properties of
the scaffolds.
The plasticity of BMCs has important implications in
tissue engineering of cardiovascular systems. It has been re-
ported that BMCs have the capability of differentiating into
ECs6-8 and vascular SMCs,9-11 and BMCs have been shown
as a feasible cell source for the engineering of cardiovascular
tissues in animals13-15,24,27,28 and humans.25,26 Immuno-
fluorescent double-staining results in this study revealed
that BMCs seeded onto hybrid biodegradable polymer
patch scaffolds contributed to regeneration of endothelium
and SM in vivo. These results are consistent with the
findings of a previous report, in which autologous
BMMNCs seeded onto biodegradable polymer scaffolds
differentiated into ECs and vascular SMCs and regenerated
endothelium and SM tissue in canine models.24 This study
showed that CM-DiI–labeled cells were detected at 8 weeks
ed 8 weeks after implantation. (A) Calcium contents of
n and of native canine inferior venae cavae (IVCs). The
was not statistically significantly different (P	 .05) from
g of (B) tissue-engineered vascular patches (original
n, 100), and (D) native canine bone tissue (original
100 m.etriev
ntatio
 4)
tainin
ficatioafter implantation, and this is consistent with the findings of
scale
400
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can be observed up to 8 weeks14,15 and 130 days29 in vivo.
However, the number of CM-DiI–labeled cells seemed
rather small at 8 weeks. This might be due to a signal
dilution of membrane-incorporated dye by labeled cell
division, infiltration by host SMCs, or both. Considering
that no anticoagulants or antiplatelets were administered to
animals after surgery in this study, BMC seeding could
provide tissue-engineered vascular patches with antithrom-
bogenic potential.
In the clinical fields, most of vascular grafts are implanted
into the arterial position. Thus, most of the animal experi-
ments have focused on implantation of vascular grafts into the
arterial system. However, because the diameters of the ab-
dominal aorta and femoral artery in the canine model are less
than 6 mm, the anastomosis of a patch (15 mm wide  30
mm long) into the vascular wall of these arteries is difficult
because of the size discrepancy between the patch and native
vessel. Therefore, in this study, we chose the IVC as an
anastomotic vessel. Previous studies reported that the in vivo
behaviors of vascular grafts implanted into the venous and
arterial systems in animal models were similar between the
Fig 9. Immunofluorescent double staining of tissue-eng
A, Immunofluorescent staining for von Willebrand fac
luminal sides of the patches (original magnification, 20
1,1=-dioactadecyl-3,3,3=,3=-tetramethylindocarbocyanin
in the luminal sides of patches retrieved at 8 weeks (orig
image of vWF-positive cells and CM-DiI–labeled ce
D, Immunofluorescent staining for smooth muscle (SM)
of patches (original magnification,400; scale bar 50
parts of retrieved patches (original magnification,400;
cells and CM-DiI–labeled cells (original magnification, venous and arterial systems.30,31 To test the feasibility oftissue-engineered vascular patches in clinical application, an
additional experiment of implanting vascular grafts into a
large-diameter arterial position would be necessary. Patches
for reconstruction of the vascular wall are necessary in the
venous system as well as the arterial system.32 Several studies
have tested tissue-engineered vascular patches for reconstruc-
tion of venous walls in animals32 and humans.25 Thus, tissue-
engineered vascular patches developed in this study could be
used for reconstruction of veins such as hepatic vein or IVC.
The tissue-engineering method for vascular patch con-
struction in this study needs to be further improved and
characterized. BMCs used in this study were derived from
young animals. The use of BMCs derived from elderly bone
marrow donors, who have a frequent occurrence of vascular
diseases, may result in unsatisfactory tissue formation in engi-
neering of vascular tissues. It was reported that increased bone
marrow donor age reduces the number of stem or progenitor
cells in bone marrow and their proliferation and differentia-
tion capacity.33,34 Indeed, the increase in donor age adversely
affected the efficacy of cellular therapy by BMCs for myocar-
dial regeneration33 and bone formation.34 Thus, methods
for enrichment and activation of stem or progenitor cells
ed vascular patches retrieved 8 weeks after implantation.
vWF) showed endothelium (green) formation on the
ale bar  100 m). B, Cells labeled with chloromethyl-
hlorate (CM-DiI; red) before implantation were present
agnification, 200; scale bar  100 m). C, Merged
riginal magnification, 200; scale bar  100 m).
in showed SM (green) regeneration in the medial regions
E,CM-DiI–labeled cells (red)were present in the medial
bar 50 m). F, Merged image of SM -actin–positive
; scale bar  50 m).ineer
tor (
0; sc
e perc
inal m
lls (o
-act
m).may be required for elderly patients. The use of animal
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evoke immune response or inflammation in cell-recipient
dogs. The use of autologous serum could increase the
applicability of the tissue-engineered vascular patches for
the human clinical setting. Characteristics of the tissue-
engineered vascular patches, including mechanical prop-
erties and vasoreactivity, should be further evaluated in
additional experiments. The mechanical properties (e.g.,
tensile strength and burst strength) of in vivo engineered
vascular patches should be measured and compared with
those of native blood vessels. Imaging analyses such as
duplex scan, magnetic resonance imaging, and angiog-
raphy would be necessary to examine narrowing of the
patches in additional studies. Because we did not use
autologous serum for BMC culture or exclude migration
by host cells in this study, examination of scaffolds with
no cell seeding would be necessary to reveal whether
acellular scaffolds could be sufficient as a vascular patch.
In summary, we developed a tissue-engineered vascular
patch by using autologous BMCs and a hybrid biodegradable
polymer scaffold fabricated from PLCL copolymer and PGA
fibers. Tissue-engineered vascular patches remained patent at
8 weeks after implantation and demonstrated vascular tissue
regeneration in canine models. However, because this study is
a preliminary work with a small number (n 4) of animals at
one time point (8 weeks), the tissue-engineered vascular
patches should be further tested in a large number of animals
at earlier and longer time points. Additional studies are needed
to evaluate the clinical potential of these vascular patches.
Vascular patch characteristics such as patency, thrombosis,
calcification, aneurysmal dilatation, and vasoreactivity should
also be assessed in long-term animal studies. Additionally,
experiments of vascular patch implantation into growing ani-
mals are necessary to determine the growth potential of tissue-
engineered vascular patches, which could be useful for treat-
ing pediatric patients.
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